Table 2 2a. Aortic regurgitation incidence (percent per year) estimated from Framingham Study prevalence (Singh, et al, 1999). Prevalence of mild or greater aortic regurgitation utilized.
From: Risk of valvular heart disease associated with use of fenfluramine
Men | Women | |||||
|---|---|---|---|---|---|---|
Age | N | Prevalence (%) | Incidence | N | Prevalence (%) | Incidence |
26–39 | 91 | 0 | - | 93 | 0 | - |
40–49 | 352 | 1.7 | 0.171 | 451 | 0.7 | 0.070 |
50–59 | 433 | 4.2 | 0.253 | 515 | 2.1 | 0.141 |
60–69 | 359 | 12.7 | 0.884 | 390 | 6.8 | 0.480 |
70–83 | 91 | 14.4 | 0.132 | 90 | 16.9 | 0.816 |
2b. Mitral regurgitation incidence estimated from Framingham Study prevalence rates (Singh, et al, 1999). Prevalence of moderate or greater mitral regurgitation utilized. | ||||||
Men | Women | |||||
Age | N | Prevalence (%) | Incidence | N | Prevalence (%) | Incidence |
26–39 | 91 | 0 | - | 93 | 0 | - |
40–49 | 351 | 0.3 | 0.030 | 452 | 0.9 | 0.090 |
50–59 | 432 | 1.6 | 0.131 | 515 | 1.0 | 0.010 |
60–69 | 372 | 2.4 | 0.080 | 395 | 2.3 | 0.131 |
70–83 | 90 | 11.2 | 0.706 | 90 | 0.0 | 0.000 |